Efficacy of Avatrombopag in Thrombocytopenic Patients With Chronic Liver Disease Undergoing an Elective Procedure
Status:
Recruiting
Trial end date:
2022-04-30
Target enrollment:
Participant gender:
Summary
In this study, investigators aimed to evaluate the efficacy of Avatrombopag in
thrombocytopenic patients with chronic liver disease undergoing an elective invasive
procedure through a prospective, non-randomized controlled, multicenter clinical trial. The
patients were non-randomly assigned to the Avatrombopag group (119 patients) and the
conventional treatment group (357 patients). The primary endpoint was the proportion of
patients not requiring prophylactic platelet transfusion or rescue therapy due to bleeding
from grouping up to 10 days post-procedure. Second endpoints included the proportion of
patients achieving a platelet count of ≥50x10^9/L and the mean change in platelet count from
baseline at the time before the procedure, the proportion of patients requiring platelet
transfusion and the mean platelet transfusion units per capita, the incidence of bleeding
events (WHO≥2 and requiring rescue therapy), the imaging evaluations of bleeding events, the
incidence of adverse events, the changes in life quality between two groups before and after
treatment, and the pharmacoeconomic index of two groups.